These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2004037)

  • 1. Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.
    Druzgala P; Hochhaus G; Bodor N
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):149-54. PubMed ID: 2004037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
    Bodor N; Loftsson T; Wu WM
    Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
    Hochhaus G; Chen LS; Ratka A; Druzgala P; Howes J; Bodor N; Derendorf H
    J Pharm Sci; 1992 Dec; 81(12):1210-5. PubMed ID: 1491342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
    Wu WM; Bodor ET; Howes J; Bodor N
    Pharmazie; 2012 May; 67(5):406-10. PubMed ID: 22764572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural studies of loteprednol etabonate and other analogs of prednisolone using NMR techniques.
    Rachwal S; Pop E; Brewster ME
    Steroids; 1996 Sep; 61(9):524-30. PubMed ID: 8883218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and structure elucidation of the major photodegradation products of loteprednol etabonate.
    Shirasaki Y; Inada K; Inoue J; Nakamura M
    Steroids; 2004 Jan; 69(1):23-34. PubMed ID: 14715374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid activity and structure activity relationships in a series of some novel 17 alpha-ether-substituted steroids: influence of 17 alpha-substituents.
    Hochhaus G; Druzgala P; Hochhaus R; Huang MJ; Bodor N
    Drug Des Discov; 1991 Dec; 8(2):117-25. PubMed ID: 1793774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A convenient synthesis of the side chain of loteprednol etabonate--an ocular soft corticosteroid from 20-oxopregnanes using metal-mediated halogenation as a key reaction.
    Chowdhury P; Borah JM; Goswami P; Das AM
    Steroids; 2011 Apr; 76(5):497-501. PubMed ID: 21277882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comments concerning "Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs".
    Sloan KB; Perrin JH
    J Pharm Sci; 1994 Jul; 83(7):1066-8. PubMed ID: 7965668
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N; Bodor N; Wu WM
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.
    Druzgala P; Wu WM; Bodor N
    Curr Eye Res; 1991 Oct; 10(10):933-7. PubMed ID: 1959381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.
    Howes J; Novack GD
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):153-8. PubMed ID: 9572541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
    Paton DM
    Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
    Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
    J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.